Skip to Main Content

Paper Details

Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.
Clin Infect Dis
0
2023
Chronic Hepatitis C, HCV, Participants, Sofosbuvir, Velpatasvir, decompensated cirrhosis, hepatitis C virus, participant, participants, persons, sofosbuvir, velpatasvir
Author NameAffiliation
Laura SmeatonHarvard TH Chan School of Public Health
Mark S SulkowskiJohns Hopkins University School of Medicine
Gregory K RobbinsMassachusetts General Hospital, Harvard Medical School
  • 1 - 3

Datasets

Release 1.2